Trial Profile
A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients With and Without Immunosuppression
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; Immunosuppressants
- Indications Cervical cancer; Graft-versus-host disease; Human papillomavirus infections
- Focus Pharmacodynamics
- 20 Jul 2016 Status changed from active, no longer recruiting to completed.
- 05 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov.
- 21 Aug 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.